乳腺癌内科治疗新进展.pptVIP

乳腺癌内科治疗新进展 新药新方案 新理念 新药不良反应及处理 1.1白蛋白结合紫杉醇 (ABX) 1.2 EFECT: Evaluation of Treatment Options Following AI Failure EFECT: Similar TTP in Patients Treated With Fulvestrant or Exemestane EFECT: Patient Response and Study Conclusions Median duration of response to treatment with fulvestrant vs exemestane: 13.5 vs 9.8 months, respectively  Fulvestrant as effective and safe as exemestane in women with hormone receptor–positive breast cancer who have progressed on treatment with a nonsteroidal AI 1.3 Ixabepilone+Capecitabine vs Capecitabine Ixabepilone+Capecitabine vs Capecitabine Ixabepilone+Capecitabine vs Capecitabine 新药新方案 新理念 新药不良反应及处理 2.1 Lapatinib oral tyrosine kinase inhibitor of ErbB1 and ErbB2 Blocks signaling through EGFR and HER2 homodimers and heterodimers May also prevent signaling between ErbB1/ErbB2 and other ErbB family members EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer EGF100151: Lapatinib + Capecitabine in Advanced Breast Cancer (cont’d) Addition of lapatinib to capecitabine in women with treatment-refractory, advanced metastatic breast cancer associated with Longer time to progression 36.9 vs 19.7 wks (P = .00016) Longer progression-free survival 36.9 vs 17.9 wks (P = .000045) Fewer progressions or deaths 38% vs 48% Response (independent review) Overall: 22.5% vs 14.3% (P = .113) 2.2 Phase III study of Paclitaxel+Xeloda (XP) vs Paclitaxel+EPI (EP) advanced breast cancer, lueck et al Phase III study of Paclitaxel+Xeloda (XP) vs Paclitaxel+EPI (EP) EP vs XP Time to progression 11.8 m vs 12.3 m Response 41.0％ vs 41.5％ 2.4 TAnDEM 研究设计 Crossover to receive trastuzumab was actively offered to all patients who progressed on anastrozole alone Progression-free survival 2.5 HTX:HT Time to progression 新药新方案 新理念 新药不良反应及处理 3.1攻克血脑屏障的新手段 3.2 TransATAC Central Laboratory Analysis: A vs T for ER and PR Status TransATAC central laboratory analysis indicates benefit of anastrozole over tamoxifen similar for ER-positive patien